<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">Recent studies have shown that IVIg reduces the proliferation of Th17 cells, as well as decreases the production of IL-17A, IL-17F, IL-21, and CCL20 [
 <xref rid="bb0490" ref-type="bibr">98</xref>,
 <xref rid="bb0495" ref-type="bibr">99</xref>]. In other study, IVIg appeared to modulate the Th17/Treg ratio which is associated with recurrent pregnancy loss [
 <xref rid="bb0500" ref-type="bibr">100</xref>]. It is plausible that CP may act in a similar way in patients with COVID-19 [
 <xref rid="bb0140" ref-type="bibr">28</xref>,
 <xref rid="bb0145" ref-type="bibr">29</xref>] (
 <xref rid="f0005" ref-type="fig">Fig. 1</xref>C).
</p>
